{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:49:56Z","timestamp":1792194596059,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03141-y","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:14:08Z","timestamp":1751390048000},"page":"750-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Andrea","family":"Tripoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma N.","family":"Gamarra-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivraj Paneer","family":"Selvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Kaplinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Barbagelata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mara","family":"Scandroglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7271-4845","authenticated-orcid":false,"given":"Juliana","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"12","key":"3141_CR1","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/JAMA.2022.16197","volume":"328","author":"MR Mehra","year":"2022","unstructured":"Mehra MR, Goldstein DJ, Cleveland JC et al (2022) Five-Year outcomes in patients with fully magnetically levitated vs Axial-Flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA 328(12):1233\u20131242. https:\/\/doi.org\/10.1001\/JAMA.2022.16197","journal-title":"JAMA"},{"issue":"8","key":"3141_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/EURHEARTJ\/EHAD658","volume":"45","author":"JD Schmitto","year":"2024","unstructured":"Schmitto JD, Shaw S, Garbade J et al (2024) Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry. Eur Heart J 45(8):613\u2013625. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD658","journal-title":"Eur Heart J"},{"key":"3141_CR3","doi-asserted-by":"publisher","unstructured":"Meyer DM, Nayak A, Wood KL et al (2025) The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients. Ann Thorac Surg.;119(1):34\u201358. https:\/\/doi.org\/10.1016\/J.ATHORACSUR.2024.10.003","DOI":"10.1016\/J.ATHORACSUR.2024.10.003"},{"issue":"7","key":"3141_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/AOR.13116","volume":"42","author":"BK Martinez","year":"2018","unstructured":"Martinez BK, Yik B, Tran R et al (2018) Meta-Analysis of time in therapeutic range in Continuous-Flow left ventricular assist device patients receiving warfarin. Artif Organs 42(7):700\u2013704. https:\/\/doi.org\/10.1111\/AOR.13116","journal-title":"Artif Organs"},{"issue":"1","key":"3141_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/MAT.0000000000001572","volume":"68","author":"GP Macaluso","year":"2022","unstructured":"Macaluso GP, Pagani FD, Slaughter MA et al (2022) Time in therapeutic range significantly impacts survival and adverse events in destination therapy patients. ASAIO J 68(1):14\u201320. https:\/\/doi.org\/10.1097\/MAT.0000000000001572","journal-title":"ASAIO J"},{"issue":"1","key":"3141_CR6","first-page":"20","volume":"56","author":"JV Terrovitis","year":"2015","unstructured":"Terrovitis JV, Ntalianis A, Kapelios CJ et al (2015) Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device. Hellenic J Cardiol 56(1):20\u201325. https:\/\/www.embase.com\/search\/results?subaction=viewrecord &id=L602472706&from=export","journal-title":"Hellenic J Cardiol"},{"issue":"11","key":"3141_CR7","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s11748-020-01371-w","volume":"68","author":"VY Parikh","year":"2020","unstructured":"Parikh VY, Parikh UM, Moctezuma-Ramirez A et al (2020) Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices. Gen Thorac Cardiovasc Surg 68(11):1278\u20131284. https:\/\/doi.org\/10.1007\/s11748-020-01371-w","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"3141_CR8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206\u20131220. https:\/\/doi.org\/10.1056\/NEJMoa1300615","journal-title":"N Engl J Med"},{"key":"3141_CR9","doi-asserted-by":"publisher","unstructured":"Wang TY, Svensson LG, Wen J et al (2023) Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2(7). https:\/\/doi.org\/10.1056\/EVIDOA2300067","DOI":"10.1056\/EVIDOA2300067"},{"key":"3141_CR10","doi-asserted-by":"publisher","unstructured":"Andreas M, Moayedifar R, Wieselthaler G et al (2017) Increased thromboembolic events with Dabigatran compared with vitamin K antagonism in left ventricular assist device patients: A randomized controlled pilot trial. Circ Heart Fail 10(5). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003709","DOI":"10.1161\/CIRCHEARTFAILURE.116.003709"},{"key":"3141_CR11","doi-asserted-by":"publisher","unstructured":"Rogers JG (2017) Balancing bleeding and clotting. Circ Heart Fail 10(5). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004097","DOI":"10.1161\/CIRCHEARTFAILURE.117.004097"},{"issue":"22","key":"3141_CR12","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1001\/JAMA.2023.23204","volume":"330","author":"MR Mehra","year":"2023","unstructured":"Mehra MR, Netuka I, Uriel N et al (2023) Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial. JAMA 330(22):2171\u20132181. https:\/\/doi.org\/10.1001\/JAMA.2023.23204","journal-title":"JAMA"},{"issue":"9","key":"3141_CR13","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jchf.2024.04.013","volume":"12","author":"P Shah","year":"2024","unstructured":"Shah P, Looby M, Dimond M et al (2024) Evaluation of the hemocompatibility of the direct oral anticoagulant Apixaban in left ventricular assist devices: the DOAC LVAD study. JACC Heart Fail 12(9):1540\u20131549. https:\/\/doi.org\/10.1016\/j.jchf.2024.04.013","journal-title":"JACC Heart Fail"},{"issue":"6","key":"3141_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.124.069726","volume":"150","author":"I Netuka","year":"2024","unstructured":"Netuka I, Tucanova Z, Ivak P et al (2024) A prospective randomized trial of direct oral anticoagulant therapy with a fully magnetically levitated LVAD: the DOT-HM3 study. Circulation 150(6):509\u2013511. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069726","journal-title":"Circulation"},{"issue":"3","key":"3141_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MAT.0000000000001650","volume":"68","author":"KR Whitehouse","year":"2022","unstructured":"Whitehouse KR, Avula D, Kahlon T et al (2022) Apixaban: alternative anticoagulation for heartmate 3 ventricular assist device. ASAIO J 68(3):318\u2013322. https:\/\/doi.org\/10.1097\/MAT.0000000000001650","journal-title":"ASAIO J"},{"issue":"13","key":"3141_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0735-1097(24)02289-7","volume":"83","author":"AA Pillai","year":"2024","unstructured":"Pillai AA, Singh KS, McNamara-Diorio K, USE OF DIRECT ORAL ANTICOAGULANTS IN ADULTS WITH DURABLE LEFT VENTRICULAR ASSIST DEVICES et al (2024) J Am Coll Cardiol 83(13):299. https:\/\/doi.org\/10.1016\/S0735-1097(24)02289-7","journal-title":"J Am Coll Cardiol"},{"key":"3141_CR17","doi-asserted-by":"publisher","unstructured":"Slaughter MS, Pahwa S, Moore S, Samson R, Costelle D, Trivedi J (2022) Apixaban use in patients supported by durable left ventricular assist device. Circulation 146. https:\/\/doi.org\/10.1161\/circ.146.suppl_1.15728","DOI":"10.1161\/circ.146.suppl_1.15728"},{"issue":"11","key":"3141_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMOA1107039\/SUPPL_FILE\/NEJMOA1107039_DISCLOSURES.PDF","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992. https:\/\/doi.org\/10.1056\/NEJMOA1107039\/SUPPL_FILE\/NEJMOA1107039_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"22","key":"3141_CR19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMOA1310907\/SUPPL_FILE\/NEJMOA1310907_DISCLOSURES.PDF","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMOA1310907\/SUPPL_FILE\/NEJMOA1310907_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"10","key":"3141_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883\u2013891. https:\/\/doi.org\/10.1056\/NEJMOA1009638\/SUPPL_FILE\/NEJMOA1009638_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"12","key":"3141_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMOA0905561\/SUPPL_FILE\/NEJM_CONNOLLY_1139SA1.PDF","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151. https:\/\/doi.org\/10.1056\/NEJMOA0905561\/SUPPL_FILE\/NEJM_CONNOLLY_1139SA1.PDF","journal-title":"N Engl J Med"},{"issue":"24","key":"3141_CR22","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMOA0906598\/SUPPL_FILE\/NEJM_SCHULMAN_2342SA1.PDF","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352. https:\/\/doi.org\/10.1056\/NEJMOA0906598\/SUPPL_FILE\/NEJM_SCHULMAN_2342SA1.PDF","journal-title":"N Engl J Med"},{"issue":"3","key":"3141_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMOA1302507\/SUPPL_FILE\/NEJMOA1302507_DISCLOSURES.PDF","volume":"10","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A et al (2013) Oral Apixaban for the treatment of acute venous thromboembolism. Z fur Gefassmedizin 10(3):25\u201326. https:\/\/doi.org\/10.1056\/NEJMOA1302507\/SUPPL_FILE\/NEJMOA1302507_DISCLOSURES.PDF","journal-title":"Z fur Gefassmedizin"},{"issue":"7","key":"3141_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/EHJCVP\/PVAB057","volume":"8","author":"R Alcalai","year":"2022","unstructured":"Alcalai R, Butnaru A, Moravsky G et al (2022) Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial. Eur Heart J Cardiovasc Pharmacother 8(7):660\u2013667. https:\/\/doi.org\/10.1093\/EHJCVP\/PVAB057","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"3141_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355\/SUPPL_FILE\/COTR145_4.PDF","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ et al (2022) Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: Patient-Level network Meta-Analyses of randomized clinical trials with interaction testing by age and sex. Circulation 145(4):242\u2013255. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355\/SUPPL_FILE\/COTR145_4.PDF","journal-title":"Circulation"},{"key":"3141_CR26","doi-asserted-by":"publisher","first-page":"k2505","DOI":"10.1136\/BMJ.K2505","volume":"362","author":"Y Vinogradova","year":"2018","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J (2018) Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 362:k2505. https:\/\/doi.org\/10.1136\/BMJ.K2505","journal-title":"BMJ"},{"issue":"23","key":"3141_CR27","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","volume":"147","author":"J Harrington","year":"2023","unstructured":"Harrington J, Carnicelli AP, Hua K et al (2023) Direct oral anticoagulants versus warfarin across the spectrum of kidney function: Patient-Level network Meta-Analyses from COMBINE AF. Circulation 147(23):1748\u20131757. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062752","journal-title":"Circulation"},{"issue":"7","key":"3141_CR28","doi-asserted-by":"publisher","first-page":"E007231","DOI":"10.1161\/CIRCHEARTFAILURE.120.007231\/ASSET\/6D5DBCCC-C503-4DEC-A91E-463CC7E21258\/ASSETS\/GRAPHIC\/CIRCHEARTFAILURE.120.007231.FIG06.JPG","volume":"14","author":"SD Rao","year":"2021","unstructured":"Rao SD, Connor DE, Shehab S et al (2021) Ex vivo assessment of different oral anticoagulant regimens on pump thrombosis in a heartware ventricular assist device. Circ Heart Fail 14(7):E007231. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007231\/ASSET\/6D5DBCCC-C503-4DEC-A91E-463CC7E21258\/ASSETS\/GRAPHIC\/CIRCHEARTFAILURE.120.007231.FIG06.JPG","journal-title":"Circ Heart Fail"},{"issue":"23","key":"3141_CR29","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMOA0909938\/SUPPL_FILE\/NEJMOA0909938_DISCLOSURES.PDF","volume":"361","author":"MS Slaughter","year":"2009","unstructured":"Slaughter MS, Rogers JG, Milano CA et al (2009) Advanced heart failure treated with Continuous-Flow left ventricular assist device. N Engl J Med 361(23):2241\u20132251. https:\/\/doi.org\/10.1056\/NEJMOA0909938\/SUPPL_FILE\/NEJMOA0909938_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"12","key":"3141_CR30","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/J.JACC.2010.10.040","volume":"57","author":"M Strueber","year":"2011","unstructured":"Strueber M, O\u2019Driscoll G, Jansz P, Khaghani A, Levy WC, Wieselthaler GM (2011) Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 57(12):1375\u20131382. https:\/\/doi.org\/10.1016\/J.JACC.2010.10.040","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"3141_CR31","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMOA1900486\/SUPPL_FILE","volume":"380","author":"MR Mehra","year":"2019","unstructured":"Mehra MR, Uriel N, Naka Y et al (2019) A fully magnetically levitated left ventricular assist Device \u2014 Final report. N Engl J Med 380(17):1618\u20131627. doi:10.1056\/NEJMOA1900486\/SUPPL_FILE\/NEJMOA1900486_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"5","key":"3141_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/J.HEALUN.2018.03.002","volume":"37","author":"I Netuka","year":"2018","unstructured":"Netuka I, Iv\u00e1k P, Tu\u010danov\u00e1 Z et al (2018) Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study. J Heart Lung Transpl 37(5):579\u2013586. https:\/\/doi.org\/10.1016\/J.HEALUN.2018.03.002","journal-title":"J Heart Lung Transpl"},{"key":"3141_CR33","doi-asserted-by":"publisher","unstructured":"Tucanova Z, Ivak P, Gregor S et al (2023) (116) The Magentum 2 Study: Long-Term Analysis of Complete Withdrawal of Anticoagulation Therapy with the Heartmate 3 LVAD. The Journal of Heart and Lung Transplantation.;42(4):S61. https:\/\/doi.org\/10.1016\/j.healun.2023.02.132","DOI":"10.1016\/j.healun.2023.02.132"},{"issue":"10","key":"3141_CR34","doi-asserted-by":"publisher","first-page":"E008360","DOI":"10.1161\/CIRCHEARTFAILURE.120.008360\/SUPPL_FILE\/SUPPLEMENT_FINAL","volume":"14","author":"FH Sheikh","year":"2021","unstructured":"Sheikh FH, Ravichandran AK, Goldstein DJ et al (2021) Impact of race on clinical outcomes after implantation with a fully magnetically levitated left ventricular assist device: an analysis from the MOMENTUM 3 trial. Circ Heart Fail 14(10):E008360. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008360\/SUPPL_FILE\/SUPPLEMENT_FINAL","journal-title":"Circ Heart Fail"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03141-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:27:56Z","timestamp":1762939676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03141-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3141"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03141-y","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}